ArticleAntiviral research2009
Antiviral activity of geneticin against dengue virus.
Article in Antiviral research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 50 citations in OpenAlex.
- Glycan-binding properties of SARS-CoV-2 spike proteins: interactions with aminoglycoside antibiotics.Scientific reports · 2026Article
- In silico fragment-based design and pharmacophore modelling of therapeutics against dengue virus envelope protein.In silico pharmacology · 2024Article
- Geneticin shows selective antiviral activity against SARS-CoV-2 by interfering with programmed -1 ribosomal frameshifting.Antiviral research · 2022Article
- Virucidal and biodegradable specialty cellulose nonwovens as personal protective equipment against COVID-19 pandemic.Journal of advanced research · 2022Article
- Antiviral/antibacterial biodegradable cellulose nonwovens as environmentally friendly and bioprotective materials with potential to minimize microplastic pollution.Journal of hazardous materials · 2022Article
- Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2.Journal of natural products · 2021Review
- Production, Transmission, Pathogenesis, and Control of Dengue Virus: A Literature-Based Undivided Perspective.BioMed research international · 2021Review
- Oral Antibiotic Treatment of Mice Exacerbates the Disease Severity of Multiple Flavivirus Infections.Cell reports · 2018Article
- Geneticin Stabilizes the Open Conformation of the 5' Region of Hepatitis C Virus RNA and Inhibits Viral Replication.Antimicrobial agents and chemotherapy · 2016Article
- Natural products as source of potential dengue antivirals.Molecules (Basel, Switzerland) · 2014Review
- Article
- Understanding the dengue viruses and progress towards their control.BioMed research international · 2013Review
- Screening of Dengue virus antiviral activity of marine seaweeds by an in situ enzyme-linked immunosorbent assay.PloS one · 2012Article
- Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics.The Journal of antimicrobial chemotherapy · 2011Article
- Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo.Antiviral research · 2011Article
- Inactivation of the tick-borne encephalitis virus by RNA-cleaving compounds.Journal of molecular and genetic medicine : an international journal of biomedical research · 2011Article
- High-content assay to identify inhibitors of dengue virus infection.Assay and drug development technologies · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
The aminoglycoside, geneticin (G418), was recently shown to have antiviral activity against bovine viral diarrhea virus (BVDV). Since BVDV, dengue virus (DENV) and yellow fever virus (YFV) all belong to the Flaviviridae family, it seemed possible that a common step in their life cycle might be affected by this aminoglycoside. Here it is shown that geneticin prevented the cytopathic effect (CPE) resulting from DENV-2 infection of BHK cells, in a dose-dependent manner with an 50% effective concentration (EC(50)) value of 3+/-0.4microg/ml. Geneticin had no detectable effect on CPE caused by YFV in BHK cells. Geneticin also inhibited DENV-2 viral yield with an EC(50) value of 2+/-0.1microg/ml and an EC(90) value of 20+/-2microg/ml. With a CC(50) value of 165+/-5microg/ml, the selectivity index of anti-DENV activity of geneticin in BHK cells was established to be 66. Furthermore, 25microg/ml of geneticin nearly completely blocked plaque formation induced by DENV-2, but not YFV. In addition, geneticin, inhibited DENV-2 viral RNA replication and viral translation. Gentamicin, kanamycin, and the guanidinylated geneticin showed no anti-DENV activity. Neomycin and paromomycin demonstrated weak antiviral activity at high concentrations. Finally, aminoglycoside-3'-phosphotransferase activity of neomycin-resistant gene abolished antiviral activity of geneticin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.